Is CUE or CYRX more undervalued in 2026?

CirclFi compares Cue Biopharma, Inc. (CUE) and CryoPort, Inc. (CYRX) using 13 institutional-grade valuation models. CUE has a Quality of Company score of 5.6/10 while CYRX scores 6.7/10.

Which is a better buy — CUE or CYRX?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do CUE and CYRX valuations compare?

CUE at $21.90 and CYRX at $15.69 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

CUE vs CYRX Valuation Comparison 2026 — Intrinsic Value Analysis

CUE

Pharmaceutical Preparations

Cue Biopharma, Inc.

Quality

5.6

out of 10

Value Trap

LOW

Price

$21.90

Last close

Models

9/13

Active

CYRX

Pharmaceutical Preparations

CryoPort, Inc.

Quality

6.7

out of 10

Value Trap

—

Price

$15.69

Last close

Models

13/13

Active

Model-by-Model Comparison

Model	Type	CUE Fair Value	CUE Upside	CYRX Fair Value	CYRX Upside
Bayesian DCF	Intrinsic	$7.04	-67.9%	$5.63	-64.1%
Earnings Power Value	Intrinsic	—	—	$25.98	+151.0%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$16.78	-23.4%	$3.22	-79.4%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for CUE vs CYRX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

CUE vs CYRX — Which Stock Is More Undervalued?

CYRX scores higher with a 6.7/10 quality rating vs CUE's 5.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Cue Biopharma, Inc. (CUE) and CryoPort, Inc. (CYRX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

CUE currently trades at $21.90 with a QOC of 5.6/10, while CYRX trades at $15.69 with a QOC of 6.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).